Zentalis Pharmaceuticals

Company snapshot

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clini

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Zentalis Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 36

• Peer + 0 momentum

  ME Therapeutics

  TA overlap score 32.6

• Peer + 0 momentum

  ALX ONCOLOGY HOLDINGS

  TA overlap score 32.6

• Peer + 0 momentum

  MEREO BIOPHARMA GROUP

  TA overlap score 29.4

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  RIGEL PHARMACEUTICALS

  TA overlap score 27.2

• Peer + 0 momentum

  Genmab

  TA overlap score 25.8

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 25

Recent activity

Latest pipeline, patent, and corporate events for Zentalis Pharmaceuticals.

1. Jun 5, 2026 Clinical update

   Investigator's choice of Chemotherapy — Phase 3

2. Jun 5, 2026 Clinical update

   azenosertib — Phase 2

3. May 26, 2026 Clinical update

   ZN-d5 — Phase 1

4. May 23, 2026 Clinical update

   Azenosertib — Phase 2

5. May 23, 2026 Clinical update

   Azenosertib — Phase 2

View all clinical trial activity →

• What is Zentalis Pharmaceuticals?

  Zentalis Pharmaceuticals (United is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker ZNTL. Primary therapeutic focus areas include Ovarian Cancer, Breast Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Osteosarc

• Is Zentalis Pharmaceuticals publicly traded?

  Yes. Zentalis Pharmaceuticals is listed with ticker ZNTL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Zentalis Pharmaceuticals develop or market?

  We link 4 drug profile(s) where Zentalis Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zentalis-pharmaceuticals#company-drugs.

• What are the latest developments for Zentalis Pharmaceuticals?

  In the last 12 months our linked public records show 14 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Zentalis Pharmaceuticals focus on?

  Zentalis Pharmaceuticals focuses on Ovarian Cancer, Breast Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer based on our analysis of their pipeline programs and drug development activities.